ALEXION PHARMACEUTICALS, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 1992-01-01
- Employees
- 3.8K
- Market Cap
- -
- Website
- http://www.alexion.com
Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With AL Amyloidosis
Phase 1
Completed
- Conditions
- AL Amyloidosis
- Interventions
- Drug: Chimeric Fibril-Reactive Monoclonal Anti-body 11-1F4
- First Posted Date
- 2014-09-22
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT02245867
- Locations
- 🇺🇸
Columbia University Medical Center, New York, New York, United States
A Phase 2A Study of ALXN1007 in Participants With Newly Diagnosed Acute Lower Gastrointestinal Graft-Versus-Host Disease
Phase 2
Terminated
- Conditions
- GIGVHDAcute Graft-Versus-Host Disease
- Interventions
- Biological: ALXN1007 10 mg/kg once weeklyBiological: ALXN1007 20 mg/kg twice weeklyBiological: ALXN1007 20 mg/kg once weekly
- First Posted Date
- 2014-09-19
- Last Posted Date
- 2019-01-03
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT02245412
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸Abramson Cancer Perelman Center for Advanced Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸Washington University in St. Louis, Saint Louis, Missouri, United States
Non-interventional Substudy of ALX-HPP-502 to Assess Natural History of Patients With Juvenile-onset HPP Who Served as Historical Controls in ENB-006-09
Completed
- Conditions
- HypophosphatasiaBone Disease
- Interventions
- Biological: Retrospective Case Only
- First Posted Date
- 2014-09-10
- Last Posted Date
- 2019-03-13
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT02235493
Clinical Study In Infants With Rapidly Progressive Lysosomal Acid Lipase Deficiency
- First Posted Date
- 2014-07-18
- Last Posted Date
- 2019-11-18
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT02193867
Prevention of Delayed Graft Function Using Eculizumab Therapy (PROTECT Study)
- First Posted Date
- 2014-05-22
- Last Posted Date
- 2018-12-17
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 288
- Registration Number
- NCT02145182
- Locations
- 🇧🇷
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Phase IIa Trial of ALXN1007 for the Treatment of Non-criteria Manifestations of Antiphospholipid Syndrome
Phase 2
Terminated
- Conditions
- Antiphospholipid (aPL)-Positive
- Interventions
- Biological: Study Drug- ALXN1007
- First Posted Date
- 2014-05-01
- Last Posted Date
- 2017-07-13
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT02128269
- Locations
- 🇫🇷
Hopital Claude Huriez - CHU Lille, Lille, Nord, France
🇫🇷Hôpital Cochin, Paris, France 75679, France
🇯🇵Hokkaido University Hospital, Sapporo-shi, Hokkaido 060-8648, Japan
Safety and Efficacy Study of Sebelipase Alfa in Participants With Lysosomal Acid Lipase Deficiency
- First Posted Date
- 2014-04-14
- Last Posted Date
- 2019-12-04
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 31
- Registration Number
- NCT02112994
Retrospective, Non-interventional Natural History of Patients With Juvenile-onset Hypophosphatasia (HPP)
Completed
- Conditions
- Hypophosphatasia (HPP)
- First Posted Date
- 2014-04-04
- Last Posted Date
- 2019-04-01
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT02104219
Evaluation of Blood Brain Barrier Integrity and Structural Abnormalities in MPS IIIB Patients Using Multimodal Magnetic Resonance Imaging
Completed
- Conditions
- MPS IIIB (Sanfilippo B Syndrome)
- First Posted Date
- 2014-03-18
- Last Posted Date
- 2016-06-27
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT02090179
An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients
Phase 3
Completed
- Conditions
- Neuromyelitis Optica Spectrum DisorderNeuromyelitis Optica
- Interventions
- Biological: eculizumab
- First Posted Date
- 2013-12-06
- Last Posted Date
- 2022-08-23
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 119
- Registration Number
- NCT02003144
- Locations
- 🇺🇸
Mayo Clinic Arizona, Scottsdale, Arizona, United States
🇺🇸The Research Center of Southern California, Oceanside, California, United States
🇺🇸Georgetown University Hospital, Washington, District of Columbia, United States
© Copyright 2025. All Rights Reserved by MedPath